Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $1.0 billion.

  • Arrowhead Pharmaceuticals' Total Liabilities rose 815.98% to $1.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 billion, marking a year-over-year increase of 815.98%. This contributed to the annual value of $881.9 million for FY2025, which is 704.72% down from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Total Liabilities of $1.0 billion as of Q4 2025, which was up 815.98% from $881.9 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Total Liabilities ranged from a high of $1.0 billion in Q4 2025 and a low of $251.3 million during Q1 2022
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Total Liabilities value was $456.2 million (recorded in 2023), while the average stood at $541.1 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 49398.16% in 2021, then crashed by 1925.71% in 2022.
  • Arrowhead Pharmaceuticals' Total Liabilities (Quarter) stood at $266.0 million in 2021, then soared by 86.15% to $495.1 million in 2022, then dropped by 8.59% to $452.6 million in 2023, then soared by 111.59% to $957.6 million in 2024, then grew by 8.16% to $1.0 billion in 2025.
  • Its Total Liabilities stands at $1.0 billion for Q4 2025, versus $881.9 million for Q3 2025 and $858.3 million for Q2 2025.